Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
Provided By GlobeNewswire
Last update: Jan 8, 2024
Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma
MultiTAA-specific T cell therapies demonstrate clinical safety and positive clinical data across multiple indications
Read more at globenewswire.com
